REG - ConvaTec Group PLC - Scrip Dividend- total issued shares

ConvaTecAnnouncement

26/04/2018 07:06

2018-04-26T06:01:19.886Zreuters.comtag:reuters.com,2018-04-26:newsml_RSZ1273Ma:13TXT
This file is provided for EAP sample purposes only; it's structure and detail are subject to change, and should not be used as a definitive reference for actual development and processing.2018-04-26T06:01:19.886Z2018-04-26T06:01:19.886Z____UCDP:parsn_lse_10.54.4.69_1.2.37102:2019-05-26T06:01:19.886Z3RSZ1273MaREG - ConvaTec Group PLC  - Scrip Dividend- total issued sharesHealthcare (TRBC level 1)Pharmaceuticals & Medical Research (TRBC level 2)LEGACY: Pharmaceuticals (TRBC level 3)LEGACY: Generic & Specialty Pharmaceuticals (TRBC)Proprietary & Advanced Pharmaceuticals (TRBC level 5)Pharmaceuticals (TRBC level 4)Western EuropeUnited KingdomEuropeSuggested SourcesNews AnnouncementsRegulatory Corporate News AnnouncementsCompany NewsEurope daily earnings hits & missesConvaTec Group PLC








RNS Number : 1273M
ConvaTec Group PLC
26 April 2018
 

 
Scrip Dividend - total issued shares
 
Reading, United Kingdom (26 April 2018)
On 13 February 2018, the Board of Directors of ConvaTec Group Plc ("ConvaTec" or "the Company") proposed a final dividend in respect of 2017 subject to shareholder approval at the Annual General Meeting on 10 May 2018 of 4.3 cents per share (the "final dividend"). This final dividend is to be paid on 17 May 2018 to shareholders on the share register as at 6 April 2018. The dividend is payable in cash in Sterling to holders of ordinary shares. On 15 February 2018, the Company announced that a Scrip Dividend Scheme will be made available for this final dividend allowing shareholders to elect to receive their dividend in the form of new ordinary shares. The calculation price for the scrip dividend scheme was announced on 12 April 2018.
It is confirmed that 9,623,305 ordinary shares of 10 pence each will be allotted and issued on 17 May 2018 by the Company to those shareholders who elected to receive the scrip dividend alternative. The shares will rank pari passu with the existing issued ordinary shares of the Company. Application will be made to the Financial Conduct Authority for the shares to be admitted to the Official List and to the London Stock Exchange for the shares to be admitted to trading.
Dealings in the shares issued under the scrip dividend scheme is expected to commence on 17 May 2018.
TIMETABLE
Key dates in respect of the Scrip Dividend Scheme for the final dividend are:




Ex-dividend Date


5 April 2018




Record Date


6 April 2018




Scrip calculation price determined


5-11 April 2018 (inclusive)




Scrip calculation price available and announced


12 April 2018




Mandate delivery deadline for Shares held in uncertificated form


3.00 p.m. on 20 April 2018




Mandate delivery deadline for Shares held in certificated form


5.00 p.m. on 20 April 2018




Announcement of the total amount of new shares to be issued


26 April 2018




Dividend payment date


17 May 2018




Dispatch of statement in accordance with section 7 of Scheme Rules and share certificates, CREST accounts credited/updated, and first day of dealings in New Shares


17 May 2018




 
Enquiries
 
Media
 
Bobby Leach, VP Group Corporate Affairs, ConvaTec                    +44 (0)7770 842 226
Alastair Elwen, Finsbury                                                                   +44 (0)207 251 3801
Analysts and Investors
 
John Crosse, VP Investor Relations, ConvaTec                             +44 (0)7500 141 435
Kirsty Law, Director Investor Relations, ConvaTec                         +44 (0)7470 909 582
investorrelations@convatec.com
 
Legal Entity Identifier Code   213800LS272L4FIDOH92
 
About ConvaTec
 
ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion devices. ConvaTec's products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about ConvaTec, please visit www.convatecgroup.com where a copy of this announcement can also be found.
 
 
# # #
 
 



This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DIVSEWFLIFASEIL